According to a recent LinkedIn post from Plantible Foods, the company has received an FDA “No Questions” Letter for its Rubi Protein ingredient, derived from isolated RuBisCO protein. The post suggests Plantible views this as a regulatory and industry milestone that enables large-scale commercialization of Rubi Protein in food applications.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights Rubi Protein as a highly functional and bioavailable protein designed to support better taste, nutrition, and more sustainable food production. For investors, FDA acknowledgment may reduce regulatory risk, potentially accelerating time-to-market, expanding Plantible’s addressable customer base among CPG and ingredient buyers, and strengthening its competitive position in the alternative and specialty protein segment.
As shared in the post, Plantible frames this development as an “industry-defining moment” and indicates plans to continue working closely with customers and collaborators. If commercialization progresses, this could support revenue growth prospects, improve the company’s leverage in partnership negotiations, and position Plantible as an early mover in RuBisCO-based protein ingredients within the broader food innovation and sustainability trend.